Filing summary
Issuer discrepancy: The request identifies T3 Defense Inc., but the supplied Form 10-Q is for Brilliant Acquisition Corporation, a British Virgin Islands SPAC. This summary reflects the filing provided, not a T3 Defense filing.
Business context and reporting period
Unaudited quarterly report for the three and six months ended June 30, 2022. Brilliant had not begun operating activities or generating revenue; its purpose was to complete a business combination. The filing describes a proposed combination with Nukkleus Inc. dated February 22, 2022. However, the exhibit list includes a Termination Agreement dated June 17, 2022, and the filing text does not clearly explain its effect on that proposed transaction.
Financial results and liquidity
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 | Comparable 2021 period |
|---|---|---|---|
| Operating revenue | None | None | None |
| Operating costs | $144,590 | $613,861 | $28,567; $106,978 |
| Net loss | $35,544 | $495,827 | $21,345; $41,718 |
| Net loss per share | $0.01 | $0.09 | $0.00; $0.01 |
The 2022 quarterly net loss was partly offset by $109,046 of other income, including $52,704 of trust-account interest and a $56,342 decrease in the fair value of warrant liabilities. For the six months, other income was $118,034, including $56,651 of interest and a $61,383 warrant-liability fair-value decrease. There are no operating margins to assess because the company had no operating revenue.
- Cash and trust: June 30 cash outside the trust was $39,734; trust assets were $41,549,673, versus $47,387,687 at December 31, 2021. On July 8, 2022, trust assets were moved from money market funds to cash.
- Cash flow: Six-month operating cash use was $913,769; investing activities provided $5,894,665; financing activities used $5,224,565. Ending operating cash was $39,734.
- Debt and liabilities: Current liabilities were $3,042,929, including $2,259,427 in related-party promissory notes and $670,600 due to a related party. Derivative warrant liabilities were $119,096. The company reported no long-term debt.
- Liquidity: Working-capital deficit, excluding trust assets, was $640,555. Management stated that the cash shortfall and approaching combination deadline raise substantial doubt about the company’s ability to continue as a going concern.
Changes, outlook, risks, and unusual items
- Six-month net loss increased to $495,827 from $41,718 in 2021, while operating costs rose to $613,861 from $106,978. Trust interest increased, and warrant-liability remeasurement reduced reported expenses.
- In March 2022, shareholders redeemed 633,792 shares for $6,529,259. After quarter-end, shareholders approved another extension and redeemed 1,025,281 shares for $10,742,906, approximately $10.48 per share. The business-combination deadline was extended to October 23, 2022; the Sponsor also loaned $353,000 for the extension.
- Management intended to complete a business combination or obtain another extension before the deadline. There was no assurance of additional financing or transaction completion; absent a combination or further extension, the company expected to cease operations and redeem public shares.
- The filing cites potential effects from COVID-19 and the Russia-Ukraine conflict, including market volatility and reduced availability of transaction financing. No specific financial impact was quantified.
- Management reported material weaknesses in internal control over financial reporting involving accounting for warrants and redeemable shares, and classification of extension deposits. Remediation efforts were planned, with no assurance they would be effective.
- The MD&A says the company had net income of $21,345 for the 2021 quarter, but the financial statements report a net loss of $21,345. The financial-statement figure is used above; the inconsistency warrants verification.
Important facts for investors to verify
- Confirm that this is the intended issuer: the filing is for Brilliant Acquisition Corporation, not T3 Defense Inc.
- Determine the status and consequences of the June 17, 2022 Termination Agreement in relation to the proposed Nukkleus transaction.
- Verify the effect of post-quarter redemptions and the extension on trust assets, public shares outstanding, and the October 23, 2022 deadline. The filing reports 4,451,927 ordinary shares issued and outstanding as of August 17, 2022.
- Assess available Sponsor or other financing: the filing identifies related-party borrowing but says additional funding is not committed.
- Review remediation of the disclosed material weaknesses and reconcile the 2021 quarterly net-income/net-loss discrepancy.